July 16, 2026

VectorBuilder Advances Free VectorBee Software to Help Researchers Work with Greater Control and Flexibility

VectorBuilder Advances Free VectorBee Software to Help Researchers Work with Greater Control and Flexibility

Major VectorBee update reflects VectorBuilder’s continued investment in free, researcher-first tools for genetic engineering and vector design.

CHICAGO — July 14, 2026 — VectorBuilder, a global leader in gene delivery technologies, is launching a major update to VectorBee, its acclaimed 100% free DNA software created to help researchers view, edit, annotate, and analyze DNA and protein sequences with greater control and flexibility. Best of all, users transition seamlessly from design to order, avoiding the pain point of turning vector ideas into reality.

The update reflects VectorBuilder’s ongoing investment in free tools that help researchers work through genetic engineering and vector design with less friction. VectorBee was created as a practical complement to VectorBuilder’s online vector design platform, giving researchers unlimited editing, annotation, and sequence analysis capabilities, previously only available through costly or clunky software, where utility stopped at design.

VectorBee was developed by a team of biologists and IT engineers led by Dr. Bruce Lahn, Chief Scientist of VectorBuilder. Dr. Lahn has decades of molecular biology experience and more than 100 publications, giving the software a strong scientific foundation rooted in how researchers work day-to-day. Dr. Lahn knew the importance of easy, efficient, and trustworthy vector designs.

“Vector design is one of the earliest and most important decisions in a gene delivery experiment,” said Lahn. “Researchers need tools that let them work through those decisions with flexibility and confidence. We built VectorBee to give the scientific community a free, intuitive environment for viewing, editing, annotating, and analyzing DNA and protein sequences without unnecessary complexity.”

VectorBuilder’s online Vector Design Studio remains ideal for the design needs of most researchers, with more than 80% of custom vectors designed directly through the online platform. VectorBee now features the Vector Design Wizard, giving users access to user-friendly design features as well as an additional level of control when they require more extensive customization, analysis, or sequence-level flexibility. Once users have finalized a vector design, whether a simple vector made in a few clicks or a highly complex design, VectorBee easily redirects them to VectorBuilder for cloning and downstream services. Where existing DNA software requires users to integrate cloning approaches into their design, then spend days, weeks, or longer getting the correct vector, VectorBee, together with VectorBuilder, provides a solution from concept to clone. Researchers are given time to focus on the research that matters, not the reagents that start the journey.

Since its launch in 2024, VectorBee has quickly gained traction among life sciences researchers worldwide. The software has attracted hundreds of thousands of users and has earned strong feedback from researchers who value its accessibility, user-friendliness, and flexibility.

The latest update presents VectorBee in its truest form: as a software not only for endless sequence viewing, editing, annotation, and analysis, but also for maximum, multi-modal integration with VectorBuilder’s backbones, components, and cloning capabilities. The value of the update extends beyond individual functions to support how researchers move between design decisions, sequence review, analysis, and downstream experimental steps.

“VectorBee is evolving alongside the needs of researchers,” said Lahn. “Some users need deeper editing, annotation, and sequence analysis capabilities than an online design interface can provide. The latest updates continue that work by giving researchers more flexibility while keeping the software highly intuitive and accessible.”

The software, especially the Vector Design Wizard, reflects VectorBuilder’s broader commitment to Good Vector Practice, which emphasizes designing vectors with feasibility, experimental goals, and downstream use in mind. VectorBuilder’s validated and optimized backbones and expansive database of components ensure users have a strong, reliable starting point. By giving researchers a free tool for more flexible and informed sequence design, VectorBee helps support better design decisions at the earliest stages of gene delivery work.

“Good vector design starts with understanding what you are building, why you are building it, and how design choices may affect later experimental steps. That is why VectorBee gives researchers a free, intuitive way to work through sequence design with more control. Our commitment is to keep VectorBee 100% free for all, forever, because researchers should have access to high-quality tools regardless of budget,” said Lahn.

VectorBee is available as a free download at www.vectorbee.com.

About VectorBuilder

VectorBuilder is a global leader in gene delivery technologies. As a trusted partner in thousands of labs and biotech/pharma companies around the world, VectorBuilder is a one-stop shop for the design, development, and optimization of gene delivery solutions from basic research to clinical applications. Its award-winning Vector Studio is a transformative innovation that allows researchers to easily design and order custom vectors online, freeing them from the tedious work of cloning and packaging vectors in the lab. The global company boasts high-throughput vector production capacity, vast vector and component inventories, one-on-one CRO solutions that include advanced AAV capsid engineering capabilities, and state-of-the-art GMP manufacturing facilities. With leading R&D and CDMO capabilities, the VectorBuilder team strives to provide the most effective gene-delivery solutions and develop innovative tools for life sciences research and genetic medicine.

Media Inquiries

communications@vectorbuilder.com 

Our latest News

discover more
BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

BioMed X and Boehringer Ingelheim Expand XSeed Labs to Advance Next-Generation Eye Therapies

Ridgefield, CT, USA, July 9, 2026 – BioMed X, a leading innovation engine for pharma, and Boehringer Ingelheim today announced the launch of a new research team at XSeed Labs, the established innovation incubator embedded within Boehringer’s U.S. R&D headquarters in Ridgefield, Connecticut. The newly established research team, Team NIB (New Platform for Next-Generation Intraocular […]

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Clinical Trial on Mild Stroke: Inpatient or Outpatient Treatment?

Researchers at Heidelberg University’s Faculty of Medicine are investigating a new care model for older adults with mild strokes at the Heidelberg University Hospital’s Department of Neurology. The Joint Federal Committee (G-BA) is funding the ARTIFICE study with approximately 2.4 million euros. Full Text in German below. Klinische Studie zu leichtem Schlaganfall: stationär oder ambulant […]

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

VERAXA Biotech to Launch AI-enabled Drug Discovery Collaboration with Ardigen to Support Growing BiTAC® Pipeline

Ardigen platform supports VERAXA’s in-house AI capabilities to optimize cancer target pair selection for conditionally active t cell engagers (TCEs) and antibody drug conjugates (ADCs) ZURICH, SWITZERLAND – July 13, 2026 — VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today announced a collaboration with Ardigen S.A., an AI-driven computational partner for modern […]

GET IN TOUCH

Stay Updated with bioRN’s Newsletter

Sign up for our newsletter to discover more!
* required

BioRN (BioRN Network e.V. and BioRN Cluster Management GmbH) will use the information you provide on this form to be in touch with you and to provide updates and marketing. Please let us know all the ways you would like to hear from us:

You can update your subscription preferences or unsubscribe at any time. Just follow the unsubscribe or update link in the footer of automated emails you receive from us, or by contacting us at info@biorn.org. We will treat your information with respect. For more information about our privacy practices please visit our website: www.biorn.org. By clicking below, you agree that we may process your information in accordance with these terms.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices.

Intuit Mailchimp